The Peter Attia Drive
#393 ‒ AMA #85: A Guide to Medications and Supplements: Determining What to Take, What to Skip, and How to Know if They're Working for You
Why It Matters
Understanding how to rigorously assess drugs and supplements helps listeners avoid wasted money, unnecessary side effects, and false hopes, especially as the supplement market booms. By applying these decision‑making frameworks, individuals can make safer, more effective health choices that align with their specific goals.
Key Takeaways
- •Define health problems with metric, threshold, timeline.
- •Classify interventions: treatment, symptom relief, risk reduction, optimization.
- •Evidence standards rise for treatment and risk reduction.
- •Optimization supplements require highest skepticism due to placebo.
- •Consider side effects, cost, hassle, opportunity cost.
Pulse Analysis
Peter Atiyah stresses that successful health decisions start with a precise problem definition rather than a vague desire for more energy or longevity. He recommends identifying a quantifiable metric, a target threshold, and a realistic time horizon—examples include lowering APOB from 130 mg/dL to under 60 mg/dL within six months or reducing sleep latency from 60 to under 10 minutes in two months. This disciplined framing creates a falsifiable hypothesis, clarifies the counterfactual of doing nothing, and prevents the storytelling bias that lets minor fluctuations masquerade as real improvement.
Once the problem is nailed down, Atiyah categorizes any medication or supplement into four ‘jobs’: disease treatment, symptom relief, risk reduction, and optimization. The evidence bar rises sharply for treatment and risk‑reduction claims, demanding hard‑outcome trials or validated surrogate biomarkers such as APOB rather than vague inflammatory indices. Symptom‑relief interventions can tolerate modest evidence and lower safety thresholds because the benefit is subjective. In contrast, optimization products—often marketed for longevity—offer tiny effect sizes, rely on mechanistic arguments, and therefore merit the highest level of skepticism before any cost, side‑effect, or opportunity‑cost analysis is undertaken.
The practical takeaway for executives and health‑conscious professionals is to run a simple decision checklist: confirm a measurable target, verify that the intervention’s job matches the evidence tier, and calculate real downside—including price, administration hassle, and opportunity cost of alternative therapies. Strong evidence should be a prerequisite for any claim that purports to reduce disease risk, while optimization supplements should be abandoned unless they demonstrate clear, cost‑effective benefit. By applying this framework, organizations can avoid wasted spend on low‑value products and focus resources on interventions with demonstrable health‑outcome returns.
Episode Description
View the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter's Weekly Newsletter
In this "Ask Me Anything" (AMA) episode, Peter explores how to think critically about medications and supplements by focusing not on whether an intervention is inherently "good" or "bad," but on whether it makes sense for a specific person with a specific problem. He explains why clearly defining the problem matters more than choosing the intervention itself, how the intended purpose of a medication or supplement should influence the standard of evidence required, and why mechanistic reasoning alone is rarely enough to justify taking something. Peter also examines how baseline risk shapes the true benefit of an intervention, why relative risk statistics can be misleading without proper context, and how to weigh not only side effects, but also cost, inconvenience, and opportunity cost when deciding whether something is worth taking. Additionally, he discusses practical ways to evaluate whether a supplement is actually having a meaningful effect, how to think about discontinuing therapies, why supplements deserve far more skepticism than they often receive, and the small group of over-the-counter supplements he believes may offer a reasonable risk-reward trade-off.
If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #85 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.
We discuss:
How to properly define health problems before considering medications or supplements [1:45];
How the intended purpose of an intervention should determine evidence standards and risk tolerance [5:00];
Understanding the hierarchy of evidence for medications and supplements and avoiding the mistake of treating weak evidence as clinical proof [9:00];
Why mechanistic explanations can be misleading when evaluating longevity interventions [13:15];
How baseline risk—and the distinction between relative and absolute risk reduction—changes the real-world benefit of medications and supplements [18:15];
Thinking beyond side effects: the many forms of downside associated with medications and supplements [22:45];
Why medications and supplements require different standards of trust and evidence [26:00];
How to structure meaningful self-experiments with medications and supplements to determine if it's they're working [30:30];
How to monitor the effects of medications and supplements without fooling yourself [32:30];
How to periodically reevaluate and potentially discontinue medications and supplements [35:15];
The biggest risks and failure modes of over-the-counter supplements: efficacy, poor quality control, contamination, interactions, toxicity, and marketing-driven overuse [38:30];
Why the US supplement regulatory system creates unreliable products [41:45];
A practical framework for evaluating medications and supplements [46:30];
Over-the-counter supplements with the best balance of evidence and low downside risk [48:00]; and
More.
Connect With Peter on Twitter, Instagram, Facebook and YouTube
Comments
Want to join the conversation?
Loading comments...